Back to Search
Start Over
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
- Source :
-
Journal of medical economics [J Med Econ] 2024 Jan-Dec; Vol. 27 (1), pp. 866-879. Date of Electronic Publication: 2024 Jul 04. - Publication Year :
- 2024
-
Abstract
- Aims: To describe healthcare resource utilization (HCRU) and associated costs after initiation of injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy by adult patients with type 2 diabetes (T2D) in the prospective, observational, 24-month TROPHIES study in France, Germany, and Italy.<br />Materials and Methods: HCRU data for cost calculations were collected by treating physicians during patient interviews at baseline and follow-up visits approximately 6, 12, 18, and 24 months after GLP-1 RA initiation with once-weekly dulaglutide or once-daily liraglutide. Costs were evaluated from the national healthcare system (third-party payer) perspective and updated to 2018 prices.<br />Results: In total, 2,005 patients were eligible for the HCRU analysis (1,014 dulaglutide; 991 liraglutide). Baseline patient characteristics were generally similar between treatment groups and countries. The largest proportions of patients using ≥2 oral glucose-lowering medications (GLMs) at baseline (42.9-43.4%) and month 24 (44.0-45.1%) and using another injectable GLM at month 24 (15.3-23.2%) were in France. Mean numbers of primary and secondary healthcare contacts during each assessment period were highest in France (range = 4.0-10.7) and Germany (range = 2.9-5.7), respectively. The greatest proportions (≥60%) of mean annualized costs per patient comprised medication costs. Mean annualized HCRU costs per patient varied by treatment cohort and country: the highest levels were in the liraglutide cohort in France (€909) and the dulaglutide cohort in Germany (€883).<br />Limitations: Limitations included exclusion of patients using insulin at GLP-1 RA initiation and collection of HCRU data by physician, not via patient-completed diaries.<br />Conclusions: Real-world HCRU and costs associated with the treatment of adults with T2D with two GLP-1 RAs in TROPHIES emphasize the need to avoid generalization with respect to HCRU and costs associated with a particular therapy when estimating the impact of a new treatment in a country-specific setting.
- Subjects :
- Humans
Male
Female
Prospective Studies
Middle Aged
Aged
Health Resources statistics & numerical data
Health Resources economics
Models, Econometric
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 economics
Liraglutide therapeutic use
Liraglutide economics
Glucagon-Like Peptides analogs & derivatives
Glucagon-Like Peptides therapeutic use
Glucagon-Like Peptides economics
Glucagon-Like Peptides administration & dosage
Immunoglobulin Fc Fragments therapeutic use
Immunoglobulin Fc Fragments economics
Recombinant Fusion Proteins economics
Recombinant Fusion Proteins therapeutic use
Recombinant Fusion Proteins administration & dosage
Hypoglycemic Agents therapeutic use
Hypoglycemic Agents economics
Subjects
Details
- Language :
- English
- ISSN :
- 1941-837X
- Volume :
- 27
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of medical economics
- Publication Type :
- Academic Journal
- Accession number :
- 38963346
- Full Text :
- https://doi.org/10.1080/13696998.2024.2367919